Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 20/20 | 0.66 |
| ▸ | CTSD | P07339 | 13/20 | 0.66 |
| ▸ | BACE2 | Q9Y5Z0 | 14/20 | 0.55 |
| ▸ | APP | P05067 | 1/20 | 0.51 |
| ▸ | REN | P00797 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4890174 | 0.94 | BACE1 (0.60) | BACE1CTSDBACE2APP | |
| SCHEMBL4890689 | 0.89 | BACE1 (0.70) | BACE1CTSDBACE2APPREN | |
| SCHEMBL4892545 | 0.86 | BACE1 (0.68) | BACE1CTSDBACE2APPREN | |
| SCHEMBL4891730 | 0.86 | BACE1 (0.65) | BACE1CTSDBACE2APPREN | |
| SCHEMBL4881405 | 0.86 | BACE1 (0.74) | BACE1CTSDBACE2APPREN | |
| SCHEMBL5097081 | 0.85 | BACE1 (0.63) | BACE1CTSDBACE2REN | |
| SCHEMBL4888121 | 0.85 | BACE1 (0.67) | BACE1CTSDBACE2APPREN | |
| SCHEMBL4888101 | 0.84 | BACE1 (0.61) | BACE1CTSDBACE2REN | |
| SCHEMBL4890134 | 0.84 | BACE1 (0.77) | BACE1CTSDBACE2APPREN | |
| SCHEMBL5090805 | 0.83 | BACE1 (0.62) | BACE1CTSDBACE2APPREN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007145568-A9 | AMINO-IMIDAZOLONES AND THEIR USE AS A MEDICAMENT FOR TREATING COGNITIVE IMPAIRMENT, ALZHEIMER DISEASE, NEURODEGENERATION AND DEMENTIA | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | WO | disclosed |
| WO-2007145569-A9 | AMINO-IMIDAZOLONES AND THEIR USE AS A MEDICAMENT FOR TREATING COGNITIVE IMPAIRMENT, ALZHEIMER DISEASE, NEURODEGENERATION AND DEMENTIA | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | WO | disclosed |
| US-20080058349-A1 | New Compounds 318 | ASTRAZENECA AB (SE) | 2008-03-06 | — | — | US | disclosed |
| US-20080058349-A1 | New Compounds 318 | ASTRAZENECA AB (SE) | 2008-03-06 | — | — | US | disclosed |
| US-20080058349-A1 | New Compounds 318 | ASTRAZENECA AB (SE) | 2008-03-06 | — | — | US | disclosed |
| US-20080051420-A1 | New Compounds 317 | ASTRAZENECA AB (SE) | 2008-02-28 | — | — | US | disclosed |
| US-20080051420-A1 | New Compounds 317 | ASTRAZENECA AB (SE) | 2008-02-28 | — | — | US | disclosed |
| US-20080051420-A1 | New Compounds 317 | ASTRAZENECA AB (SE) | 2008-02-28 | — | — | US | disclosed |
| WO-2007145568-A1 | AMINO-IMIDAZOLONES AND THEIR USE AS A MEDICAMENT FOR TREATING COGNITIVE IMPAIRMENT, ALZHEIMER DISEASE, NEURODEGENERATION AND DEMENTIA | ASTRAZENECA AB (SE) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007145569-A1 | AMINO-IMIDAZOLONES AND THEIR USE AS A MEDICAMENT FOR TREATING COGNITIVE IMPAIRMENT, ALZHEIMER DISEASE, NEURODEGENERATION AND DEMENTIA | ASTRAZENECA AB (SE) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058349-A1 | New Compounds 318 | PSEN2, PSEN1, MAPT | BACE1 5/4885CTSD 1887/4885BACE2 19/4885 |
| US-20080051420-A1 | New Compounds 317 | PSEN2, PSEN1, MAPT | BACE1 6/4885CTSD 2053/4885BACE2 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.